Monoclonal antibody treatment may not be available to all who qualify

To address excess demand for monoclonal antibody (mAb) therapy, BJC continues to limit the treatment to qualifying high-risk patients with positive COVID-19 tests. Even with these restrictions, demand continues to exceed our capacity. While we will strive to accommodate every qualifying referral, our clinics cannot guarantee the therapy to all eligible candidates within 10 days of symptom onset — the treatment time frame specified by the FDA. We will continue making every effort to care for all patients referred for mAb therapy and to minimize the instances in which the requests cannot be accommodated.